Galapagos NV Stock Euronext Bruxelles
Equities
GLPG
BE0003818359
Biotechnology & Medical Research
Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
26.7 EUR | 0.00% | 0.00% | 0.00% |
Sales 2024 * | 337M 361M | Sales 2025 * | 314M 336M | Capitalization | 1.75B 1.87B |
---|---|---|---|---|---|
Net income 2024 * | -44M -47.03M | Net income 2025 * | -65M -69.47M | EV / Sales 2024 * | -4.99 x |
Net cash position 2024 * | 3.43B 3.67B | Net cash position 2025 * | 3.13B 3.34B | EV / Sales 2025 * | -4.38 x |
P/E ratio 2024 * |
-27.7
x | P/E ratio 2025 * |
-20.3
x | Employees | - |
Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 74.64% |
Latest transcript on Galapagos NV
Managers | Title | Age | Since |
---|---|---|---|
Paulus Stoffels
CEO | Chief Executive Officer | 62 | 22-03-31 |
Thad Huston
DFI | Director of Finance/CFO | 54 | 23-05-31 |
Investor Relations Contact | - | 20-10-31 |
Members of the board | Title | Age | Since |
---|---|---|---|
Andrew Dickinson
BRD | Director/Board Member | 54 | Mar. 26 |
Jérôme Contamine
BRD | Director/Board Member | 66 | 22-04-25 |
Simon Sturge
BRD | Director/Board Member | 65 | 23-09-18 |
1st Jan change | Capi. | |
---|---|---|
+1.93% | 42.59B | |
+8.01% | 40.65B | |
+49.22% | 40.57B | |
-11.96% | 26.77B | |
+9.37% | 24.81B | |
-24.33% | 18.17B | |
+27.28% | 12.05B | |
-3.22% | 11.7B | |
+6.80% | 11.1B |
- Stock Market
- Equities
- GLPG Stock
- GLPG Stock